Expanded Access Program for Olaparib Tablets as Maintenance Therapy in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03079687 |
Expanded Access Status :
Approved for marketing
First Posted : March 14, 2017
Last Update Posted : October 25, 2017
|
- Study Details
- Tabular View
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Ovarian Cancer | Drug: Olaparib tablets |
Study Type : | Expanded Access |
Expanded Access Type : | Treatment IND/Protocol |
See clinical trials of the intervention/treatment in this expanded access record. | |
Official Title: | A Multiple Patient Expanded Access Program for Olaparib Tablets for the Maintenance Treatment Following Response (Complete Response or Partial Response) to Platinum-based Chemotherapy in Patients With Platinum-sensitive Relapsed High-grade Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer. |
- Drug: Olaparib tablets
Patients will receive olaparib tablets 300mg (two 150mg tablets) twice daily.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 120 Years (Adult, Older Adult) |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion criteria
For inclusion in the program patients must fulfill the following criteria:
- Provision of informed consent prior to any program specific procedures
- Female patients ≥ 18 years of age and has platinum-sensitive relapsed high grade epithelial ovarian, primary peritoneal or fallopian tube cancer
- Patient is in response (complete response or partial response) following platinum-based chemotherapy.
- Patients must have normal organ and bone marrow function measured within 28 days prior to administration of program treatment.
- Postmenopausal or evidence of non-childbearing status for women of childbearing potential.
Exclusion criteria:
Patients should not enter the program if any of the following exclusion criteria are fulfilled:
- Patients with a known hypersensitivity to olaparib or any of the excipients of the product.
- Concomitant use of known strong CYP3A inhibitors or moderate CYP3A inhibitors.
- Concomitant use of known strong or moderate CYP3A inducers. The required washout period prior to starting olaparib is 5 weeks for enzalutamide or phenobarbital and 3 weeks for other agents.
- Patient with moderate or severe hepatic impairment.
- Breast feeding women.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03079687
United States, California | |
Research Site | |
Duarte, California, United States, 91010 | |
Research Site | |
Newport Beach, California, United States, 92663 | |
Research Site | |
Roseville, California, United States, 95661 | |
United States, Florida | |
Research Site | |
Gainesville, Florida, United States, 32608 | |
United States, Maine | |
Research Site | |
Scarborough, Maine, United States, 04074 | |
United States, Maryland | |
Research Site | |
Baltimore, Maryland, United States, 21201 | |
United States, Minnesota | |
Research Site | |
Rochester, Minnesota, United States, 55905 | |
United States, Missouri | |
Research Site | |
Columbia, Missouri, United States, 65212 | |
United States, New Mexico | |
Research Site | |
Albuquerque, New Mexico, United States, 87106 | |
United States, North Carolina | |
Research Site | |
Durham, North Carolina, United States, 27710 | |
Research Site | |
Winston-Salem, North Carolina, United States, 27157-1023 | |
United States, Ohio | |
Research Site | |
Cleveland, Ohio, United States, 44195 | |
United States, Oregon | |
Research Site | |
Portland, Oregon, United States, 97239 |
Responsible Party: | AstraZeneca |
ClinicalTrials.gov Identifier: | NCT03079687 |
Other Study ID Numbers: |
D0816R00014 |
First Posted: | March 14, 2017 Key Record Dates |
Last Update Posted: | October 25, 2017 |
Last Verified: | October 2017 |
Ovarian cancer gynaecological cancer platinum-sensitive disease platinum-sensitive relapsed Olaparib Ovarian Neoplasms Neoplasms |
Ovarian Disease fallopean tube cancer primary peritoneal cancer epithelial ovarian cancer PARP inhibitors Poly (ADP-ribose) polymerase inhibitors. |
Ovarian Neoplasms Carcinoma, Ovarian Epithelial Endocrine Gland Neoplasms Neoplasms by Site Neoplasms Ovarian Diseases Adnexal Diseases Genital Diseases, Female Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Urogenital Diseases Genital Neoplasms, Female |
Urogenital Neoplasms Genital Diseases Endocrine System Diseases Gonadal Disorders Carcinoma Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Olaparib Poly(ADP-ribose) Polymerase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Antineoplastic Agents |